Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications—narrative review - Takeaways - MDSpire

Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications—narrative review

  • By

  • João Protásio Netto

  • José Fábio Lana

  • Alexandre Parma

  • Fábio Ramos Costa

  • Rubens Martins de Andrade

  • Mariana Garcia Martins Castro

  • Claudia Tambelli

  • April 30, 2026

  • 0 min

Share

  • 1

    Fibromyalgia affects 2%-8% of the global population, with treatment outcomes remaining suboptimal despite various therapeutic approaches.

  • 2

    Histamine intolerance, linked to diamine oxidase (DAO) deficiency, may contribute to fibromyalgia pathophysiology in certain patient subgroups.

  • 3

    A study found a 74.5% prevalence of DAO deficiency-associated genetic variants in fibromyalgia patients, correlating with increased symptom severity.

  • 4

    DAO supplementation in a randomized controlled trial showed significant improvements in pain and fibromyalgia impact compared to placebo.

  • 5

    The review advocates for assessing histamine intolerance in fibromyalgia patients with gastrointestinal symptoms or treatment resistance.

Original Source(s)

Is histamine intolerance a treatable subtype of fibromyalgia? evidence and clinical implications—narrative review

  • by João Protásio Netto, José Fábio Lana, Alexandre Parma, Fábio Ramos Costa, Rubens Martins de Andrade, Mariana Garcia Martins Castro, Claudia Tambelli

  • April 30, 2026

Related Content

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Aftersensations and Lingering Pain After Examination in Patients with Fibromyalgia Syndrome

Editorial: Integrative Approaches to Fibromyalgia: Advancing Multidisciplinary Management Strategies